FIELD: biotechnology.
SUBSTANCE: invention is a binding protein for binding vascular endothelial growth factor A (VEGF-A), comprising first, second, third and fourth ankyrin repeating domains, wherein said first ankyrin repeating domain has binding specificity to human VEGF-A and comprises an amino acid sequence, which has at least 90 % amino acid sequence identity with the amino acid sequence SEQ ID NO: 18, wherein said second ankyrin repeating domain has binding specificity to human hepatocyte growth factor (HGF) and comprises an amino acid sequence, which has at least 90 % amino acid sequence identity with the amino acid sequence SEQ ID NO: 26, and wherein each of said third and fourth engineered ankyrin repeating domains has binding specificity to human serum albumin and comprises an amino acid sequence, which has at least 90 % amino acid sequence identity with the amino acid sequence SEQ ID NO: 50.
EFFECT: recombinant binding proteins and their use are disclosed.
21 cl, 10 dwg, 9 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2778346C2 |
| BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 | 2013 |
|
RU2664464C9 |
| POLYPEPTIDES THAT BIND TO THE C5 COMPONENT OR TO SERUM ALBUMIN AND THEIR FUSION PROTEINS | 2018 |
|
RU2794359C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
